Loading stock data…
GELS
$0.66+0.01 (+1.98%)
Market ClosedLast close May 1
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gelteq Limited in the Healthcare sector is trading at $0.66. The stock is currently near its 52-week low of $0.60, remaining 39.1% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why GELS maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.66
Potential Upside
5%
Whystock Fair Value$0.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.05%
Volume
Today's trading volume
7,338
Recent News
Gelteq announces preclinical results on medicinal cannabinoid absorption
Gelteq (GELS) announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company’s proprietary oral gel platform. The findings demonstrate that Gelteq’s platform significantly enhances the absorption and bioavailability of cannabidiol compared to an existing FDA approved oil-based product. Despite having a much lower concentration of CBD, Gelteq’s formulation achieved greater than 22% increase in bioavailability along with a
Top Midday Gainers
SINTX Technologies (SINT) said Wednesday it published a peer-reviewed study demonstrating that silic